Inhalation anthrax post-exposure prophylaxis

Active Ingredient: Ciprofloxacin

Indication for Ciprofloxacin

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)
Therapeutic intent: Preventive action

Inhalation anthrax postexposure curative treatment for persons requiring parenteral treatment. Drug administration should begin as soon as possible after suspected or confirmed exposure.

Use in humans is based on in-vitro susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.

For this indication, competent medicine agencies globally authorize below treatments:

20-30 mg/kg in 2 divided doses daily

Route of admnistration

Intravenous

Defined daily dose

20 - 30 mg per kg of body weight

Dosage regimen

From 10 To 15 mg per kg of body weight 2 time(s) per day every day for 60 day(s)

Detailed description

10 mg/kg body weight twice daily to 15 mg/kg body weight twice daily with a maximum of 400 mg per dose for 60 days from the confirmation of Bacillus anthracis exposure.

Dosage considerations

Infusion time is 60 minutes for 400 mg of ciprofloxacin and 30 minutes for 200 mg of ciprofloxacin. Slow infusion into a large vein will minimise patient discomfort and reduce the risk of venous irritation.

20-30 mg/kg in 2 divided doses daily

Route of admnistration

Oral

Defined daily dose

20 - 30 mg per kg of body weight

Dosage regimen

From 10 To 15 mg per kg of body weight 2 time(s) per day every day for 60 day(s)

Detailed description

10 mg/kg body weight twice daily to 15 mg/kg body weight twice daily with a maximum of 500 mg per dose for 60 days from the confirmation of Bacillus anthracis exposure.

Dosage considerations

Infusion time is 60 minutes for 400 mg of ciprofloxacin and 30 minutes for 200 mg of ciprofloxacin. Slow infusion into a large vein will minimise patient discomfort and reduce the risk of venous irritation.

Active ingredient

Ciprofloxacin

Ciprofloxacin is a fluoroquinolone antibacterial agent. The bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.

Read more about Ciprofloxacin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.

⇈